SweetValueLab
Write for us

ResMed Inc. — Intrinsic Value & Fair Price

RMD
NYSEHealthcareMedical - Instruments & SuppliesCIK 0000943819resmed.comAbout RMD
Last close · Oct 16, 2026238.97−3.26 (−1.35%)
Market cap$33.6B
Model value · DCF · Perpetuity growth · 5y
216.26
ResMed closed at $238.97 — overvalued by 11% vs model.
146.81the model's range454.70

DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.

Other models
57.64 – 384.26
Wall St. target
251.00 5% below
Above model, 1y
5 of 20 days

Price and model value

Embed this card

RMD's close against its model value, as a 420×168 card for your own page. It updates nightly with this site and links back here.

Free to embed; keep the attribution link.
Loading chart…
What the marks mean
Daily close

Dividends

Quarterly · as of Oct 16, 2026
Yield, trailing 12 months
1.03%
Past 2 years
low 0.73%high 1.31%
Dividends per share, a year at a time
$1.59Aug ’21$1.70Aug ’22$1.80Aug ’23$1.97Aug ’24$2.19Aug ’25$2.46TTM
Dividends / free cash flow, FY2026
21.2%
Raised
13+ years in a row
Growth, 5 yrs
9.1% a year
Last change
+10.0% · Aug 2026
Every payment, with ex-dates · latest $0.66, paid Sep 24, 2026

Research on RMD

No posts on RMD yet.
Studied RMD from its filings? Guest posts are reviewed before they go live.Write about RMD →

How it is valued

Valued asMature & Stable
Low/slowing growth (~10% recent)High profitability (27% net margin)Pays dividendsHighly cyclical earnings
What growth the price implies: the reverse DCF

Key figures

FY2026
P/E
22.9×
EV / EBITDA
15.3×
FCF yield
4.8%
Dividend yield, TTM
1.03%
Beta
0.75
Cost of capital (WACC)
8.45%
Full financials

Analyst actions

third-party, quoted
10-13Mizuho Securities · target240.00
09-15RBC Capital · “Outperform” from “Sector Perform”upgrade
09-15RBC Capital · target262.00
08-31KeyBanc · target267.00
Ratings, targets and estimates

Comparable companies

by business, not by industry label
1 more company lists RMD as a comparable

The weekly

One email a week across every stock we cover: 13F filings, insider trades, earnings and new research. It covers the whole market, not just RMD. No account.

About ResMed

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

CEO
Michael J. Farrell
Headquarters
San Diego, CA
Employees
11,370
IPO
1995-06-02
Full company profile

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; the formulas are in how we value a stock.